Company Encyclopedia
View More
name
ProKidney
PROK.US
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp.
1.884 T
PROK.USMarket value -Rank by Market Cap -/-

Financial Score

18/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking111/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE7.15%B
    • Profit Margin-9547.45%E
    • Gross Margin100.00%A
  • Growth ScoreD
    • Revenue YoY0.00%C
    • Net Profit YoY-55.74%D
    • Total Assets YoY-25.94%E
    • Net Assets YoY-28.22%E
  • Cash ScoreD
    • Cash Flow Margin-1.05%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio9.46%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ProKidney (NASDAQ:PROK) Director Sells $1,190,062.32 in Stock

    ProKidney Corp. Director Brian Jg Pereira sold 502,136 shares of the company's stock for $1,190,062.32 on November 13th. The transaction was disclosed in an SEC filing. Pereira also sold 255,026 shares on November 12th for $693,670.72. ProKidney's stock rose 5.7% to $2.41, with a market cap of $709.21 million. Analysts have mixed ratings on the stock, with a consensus target price of $6.25. The company is a clinical-stage biotech firm focused on kidney disease therapies.

    Market Beat·
    US
    PROK
    +6.82%
    Market Beat·
    US
    PROK
    +6.82%

    Director’s Major Stock Sale Shakes Up ProKidney!

    Director Brian Jg Pereira sold 757,162 shares of ProKidney, totaling $1,883,733, impacting the company's stock. ProKidney presented positive Phase 2 trial results for rilparencel, supporting ongoing Phase 3 studies. Despite potential in renal therapies, Spark's AI Analyst rates PROK as Underperform due to poor financial performance and high volatility. ProKidney's YTD price performance is 31.79%, with a market cap of $806.2M.

    Tip Ranks·
    US
    PROK
    +6.82%
    Tip Ranks·
    US
    PROK
    +6.82%

    ProKidney Corp. Director Brian JG Pereira Reports Sale of Common Shares

    ProKidney Corp. Director Brian JG Pereira Reports Sale of Common Shares

    Reuters·
    US
    PROK
    +6.82%
    Reuters·
    US
    PROK
    +6.82%

    Bank of America Securities Keeps Their Sell Rating on ProKidney (PROK)

    Bank of America Securities analyst Jason Gerberry maintained a Sell rating on ProKidney (PROK) with a price target of $1.00, while the stock closed at $2.68. Gerberry, a 5-star analyst, has an average return of 10.6% and a 58.23% success rate. The overall analyst consensus for ProKidney is a Hold rating with an average price target of $4.67.

    Tip Ranks·
    US
    PROK
    +6.82%
    Tip Ranks·
    US
    PROK
    +6.82%

    Dir Pereira Files To Sell 675,234 Of ProKidney Corp [PROK]

    Brian J G Pereira, Director of ProKidney Corp [PROK], has filed a Form 144 with the SEC on November 12, 2025, to sell 675,234 shares of restricted securities through Merrill Lynch. The filing allows him to sell the shares within 90 days of submission.

    Reuters·
    US
    PROK
    +6.82%
    Reuters·
    US
    PROK
    +6.82%
    © 2025 Longbridge｜Disclaimer